Open an account

CERo Therapeutics Holdings

CERO · NASDAQ

$0.0052−$0.0009 (−14.75%)TodayMarket closed ·
Prev close $0.0061

About CERO

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Employees
8
Headquarters
South San Francisco, California
Listed
Oct 6, 2021
Sector
Health Care
Industry
Biotechnology
Website
phoenixbiotechacquisitioncorp.com

CERO key statistics

Market cap
410.50K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
711.12K
Volume
654.08K
Open price
$0.0048
High today
$0.006
Low today
$0.004
52 Week high
$2.58
52 Week low
$0.005

CERo Therapeutics Holdings (CERO) at a glance

CERo Therapeutics Holdings (CERO) last traded at $0.0052, with a market cap of 410.50K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.004 and $0.006. The current price is 30.0% above the day's low and 13.3% below its high.

Volume so far is 654.08K shares, in line with the average of 711.12K shares a day.

Over the past year CERo Therapeutics Holdings has ranged from $0.005 to $2.58, and now sits 0% of the way up that range.

CERo Therapeutics Holdings met or beat analyst EPS estimates in 1 of the last 3 quarters. In Q4 FY25 it reported -$11.45 per share against an estimate of -$0.765.

The average analyst price target is $30.60, 588361.5% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 2 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $30.60
Low
$30.30
Now
$0.0052
High
$31.50

CERO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 3 quarters, by 76.3% on average.

  1. Q1 FY25: reported -$28.80 per share against an estimate of -$121.58
  2. Q3 FY25: reported -$3.44 per share against an estimate of -$0.8976
  3. Q4 FY25: reported -$11.45 per share against an estimate of -$0.765

CERO news

  • Avi Kapoor

    Nasdaq Falls Over 1%; Alphabet Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseGlobe Newswire

    CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Avi Kapoor

    Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Dow Surges 150 Points; Korn Ferry Earnings Top Views

  • Rishabh Mishra

    US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity

Similar companies

Companies in the same industry as CERo Therapeutics Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.